Compare Abeona Therapeutics Inc (ABEO) vs Moody's Corporation (MCO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Moody's Corporation — how do they compare? Abeona Therapeutics Inc trades at $6.73 (market cap $373.32M), while Moody's Corporation trades at $485.1 (market cap $87.42B). The key difference: Moody's Corporation is far larger — about 234.2× Abeona Therapeutics Inc's market cap, and Moody's Corporation pays a 0.82% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | MCO | |
|---|---|---|
Market Cap | $373.32M | $87.42B |
Sector | Health | Financials |
52-Week High | $7.23 | $539.61 |
52-Week Low | $4.17 | $412.23 |
Enterprise Value | $228.22M | $93.23B |
Dividend Yield | — | 0.82% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
Moody's Corporation (MCO) trades at $500.49, up 2.03% with strong technical momentum and bullish moving averages. The company demonstrates robust fundamentals with 31.69% net margins and consistent earnings beats, while trading at premium valuations (P/E 35.78). Recent AI integration announcements and dividend payments highlight strategic growth initiatives.
MCO presents a compelling growth story with strong profitability and analyst support (56% buy ratings, $542 consensus target), though elevated valuations and RSI overbought signals warrant caution. Key risks include competitive pressures and market sensitivity to credit cycles, but the company's market position and AI strategy support long-term upside potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Moody's Corporation
Moody's, along with S&P Ratings, is a leading provider of credit ratings on fixed income securities. Moody's ratings segment, known as Moody's Investors Service or MIS, includes corporates, structured finance, financial institutions, and public finance ratings. MIS represents a majority of the firm's revenue and profits. Moody's other segment is Moody's Analytics and consists of Research, Data, and Analytics or RD&A and Enterprise Risk Solutions or ERS. RD&A's products include credit research, quantitative credit scores, economic research, business intelligence, know your customer (KYC) tools, commercial real estate data and analytical tools, and training services. ERS includes risk management software solutions to financial institutions.
Read more on MCO →
